Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Lung Cancer

  Free Subscription

Articles published in Mol Cancer Ther

Retrieve available abstracts of 48 articles:
HTML format

Single Articles

    July 2021
  1. MIRZAPOIAZOVA T, Xiao G, Mambetsariev B, Nasser MW, et al
    Protein phosphatase 2A as a therapeutic target in small cell lung cancer.
    Mol Cancer Ther. 2021 Jul 12. pii: 1535-7163.MCT-21-0013.
    PubMed     Abstract available

    June 2021
  2. ZHANG D, Hou Z, Aldrich KE, Lockwood L, et al
    A novel Nrf2 pathway inhibitor sensitizes Keap1-mutant lung cancer cells to chemotherapy.
    Mol Cancer Ther. 2021 Jun 22. pii: 1535-7163.MCT-21-0210.
    PubMed     Abstract available

  3. KANO H, Ichihara E, Watanabe H, Nishii K, et al
    SHP2 inhibition enhances the effects of tyrosine kinase inhibitors in preclinical models of treatment-naive ALK-, ROS1-, or EGFR-altered non-small-cell lung cancer.
    Mol Cancer Ther. 2021 Jun 22. pii: 1535-7163.MCT-20-0965.
    PubMed     Abstract available

    May 2021
  4. SUN D, Nikonova AS, Zhang P, Deneka AY, et al
    Evaluation of the small-molecule BRD4-degrader CFT-2718 in small cell lung cancer and pancreatic cancer models.
    Mol Cancer Ther. 2021 May 27. pii: 1535-7163.MCT-20-0831.
    PubMed     Abstract available

    February 2021
  5. HINZ B, Pruser JL, Ramer R, Wittig F, et al
    The monoacylglycerol lipase inhibitor JZL184 inhibits lung cancer cell invasion and metastasis via the CB1 cannabinoid receptor.
    Mol Cancer Ther. 2021 Feb 25. pii: 1535-7163.MCT-20-0589.
    PubMed     Abstract available

  6. KOHLER J, Zhao Y, Li J, Gokhale PC, et al
    ERK inhibitor LY3214996-based treatment strategies for RAS-driven lung cancer.
    Mol Cancer Ther. 2021 Feb 3. pii: 1535-7163.MCT-20-0531.
    PubMed     Abstract available

    May 2020
  7. SENTHILKUMAR G, Fisher MM, Skiba JH, Miller MC, et al
    FGFR inhibition enhances sensitivity to radiation in non-small cell lung cancer.
    Mol Cancer Ther. 2020 May 5. pii: 1535-7163.MCT-19-0931.
    PubMed     Abstract available

  8. ZENKE FT, Zimmermann A, Sirrenberg C, Dahmen H, et al
    Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models.
    Mol Cancer Ther. 2020;19:1091-1101.
    PubMed     Abstract available

  9. YAMASHITA D, Minata M, Ibrahim AN, Yamaguchi S, et al
    Identification of ALDH1A3 as a Viable Therapeutic Target in Breast Cancer Metastasis-Initiating Cells.
    Mol Cancer Ther. 2020;19:1134-1147.
    PubMed     Abstract available

    April 2020
  10. KOTANIDES H, Sattler RM, Lebron MB, Carpenito C, et al
    Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity.
    Mol Cancer Ther. 2020;19:988-998.
    PubMed     Abstract available

    March 2020
  11. FUNAZO TY, Tsuji T, Ozasa H, Furugaki K, et al
    Acquired Resistance to Alectinib in ALK-Rearranged Lung Cancer Due to ABCC11/MRP8 Overexpression in a Clinically Paired Resistance Model.
    Mol Cancer Ther. 2020 Mar 26. pii: 1535-7163.MCT-19-0649.
    PubMed     Abstract available

  12. ZHANG ZZ, Yu WX, Zheng M, Liao XH, et al
    PIN1 Inhibition Sensitizes Chemotherapy in Gastric Cancer Cells by Targeting Stem Cell-like Traits and Multiple Biomarkers.
    Mol Cancer Ther. 2020;19:906-919.
    PubMed     Abstract available

  13. SUN T, Zhang W, Li Y, Jin Z, et al
    Combination Immunotherapy with Cytotoxic T-Lymphocyte-Associated Antigen-4 and Programmed Death Protein-1 Inhibitors Prevents Postoperative Breast Tumor Recurrence and Metastasis.
    Mol Cancer Ther. 2020;19:802-811.
    PubMed     Abstract available

    February 2020
  14. XU D, Liang SQ, Yang H, Bruggmann R, et al
    CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural Mesothelioma.
    Mol Cancer Ther. 2020;19:661-672.
    PubMed     Abstract available

    November 2019
  15. TANINO R, Amano Y, Tong X, Sun R, et al
    Anticancer Activity of ZnO Nanoparticles Against Human Small-Cell Lung Cancer in an Orthotopic Mouse Model.
    Mol Cancer Ther. 2019 Nov 29. pii: 1535-7163.MCT-19-0018.
    PubMed     Abstract available

    October 2019
  16. WHALEN KA, White BH, Quinn JM, Kriksciukaite K, et al
    Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer.
    Mol Cancer Ther. 2019 Oct 24. pii: 1535-7163.MCT-19-0022.
    PubMed     Abstract available

    September 2019
  17. WANG C, Wang T, Lv D, Li L, et al
    Acquired resistance to EGFR TKIs mediated by TGF-beta1/integrin beta3 signaling in EGFR-mutant lung cancer.
    Mol Cancer Ther. 2019 Sep 9. pii: 1535-7163.MCT-19-0181.
    PubMed     Abstract available

    July 2019
  18. XU K, Sun G, Li M, Chen H, et al
    Glibenclamide targets sulfonylurea receptor 1 to inhibit p70S6K activity and upregulate KLF4 expression to suppress non-small-cell lung carcinoma.
    Mol Cancer Ther. 2019 Jul 24. pii: 1535-7163.MCT-18-1181.
    PubMed     Abstract available

  19. ANANTHARAJAN J, Zhou H, Zhang L, Hotz T, et al
    Structural and functional analyses of an allosteric Eya2 phosphatase inhibitor that has on target effects in human lung cancer cells.
    Mol Cancer Ther. 2019 Jul 8. pii: 1535-7163.MCT-18-1239.
    PubMed     Abstract available

    February 2019
  20. STAUDACHER AH, Li Y, Liapis V, Hou JJC, et al
    APOMAB Antibody-Drug Conjugates Targeting Dead Tumor Cells are Effective In Vivo.
    Mol Cancer Ther. 2019;18:335-345.
    PubMed     Abstract available

  21. PAPADAKI MA, Stoupis G, Theodoropoulos PA, Mavroudis D, et al
    Circulating Tumor Cells with Stemness and Epithelial-to-Mesenchymal Transition Features Are Chemoresistant and Predictive of Poor Outcome in Metastatic Breast Cancer.
    Mol Cancer Ther. 2019;18:437-447.
    PubMed     Abstract available

  22. CHAI D, Shan H, Wang G, Zhang Q, et al
    Combining DNA Vaccine and AIM2 in H1 Nanoparticles Exert Anti-Renal Carcinoma Effects via Enhancing Tumor-Specific Multi-functional CD8(+) T-cell Responses.
    Mol Cancer Ther. 2019;18:323-334.
    PubMed     Abstract available

    January 2019
  23. CHAN SH, Tsai KW, Chiu SY, Kuo WH, et al
    Identification of the Novel Role of CD24 as an Oncogenesis Regulator and Therapeutic Target for Triple-Negative Breast Cancer.
    Mol Cancer Ther. 2019;18:147-161.
    PubMed     Abstract available

  24. MORENO R, Fajardo CA, Farrera-Sal M, Perise-Barrios AJ, et al
    Enhanced Antitumor Efficacy of Oncolytic Adenovirus-loaded Menstrual Blood-derived Mesenchymal Stem Cells in Combination with Peripheral Blood Mononuclear Cells.
    Mol Cancer Ther. 2019;18:127-138.
    PubMed     Abstract available

  25. NAKATANI K, Yamaoka T, Ohba M, Fujita KI, et al
    KRAS and EGFR Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in EGFR.
    Mol Cancer Ther. 2019;18:112-126.
    PubMed     Abstract available

  26. LEE SS, Bindokas VP, Kron SJ
    Multiplex Three-Dimensional Mapping of Macromolecular Drug Distribution in the Tumor Microenvironment.
    Mol Cancer Ther. 2019;18:213-226.
    PubMed     Abstract available

    November 2018
  27. ZERNICKEL E, Sak A, Riaz A, Klein D, et al
    Targeting of BRM sensitizes BRG1 mutant lung cancer cell lines to radiotherapy.
    Mol Cancer Ther. 2018 Nov 26. pii: 1535-7163.MCT-18-0067.
    PubMed     Abstract available

    October 2018
  28. ABOUBAKAR NANA F, Lecocq M, Ladjemi MZ, Detry B, et al
    Therapeutic potential of Focal Adhesion Kinase inhibition in small cell lung cancer.
    Mol Cancer Ther. 2018 Oct 23. pii: 1535-7163.MCT-18-0328.
    PubMed     Abstract available

    September 2018
  29. MOCHIZUKI S, Shimoda M, Abe H, Miyamae Y, et al
    Selective inhibition of ADAM28 suppresses lung carcinoma cell growth and metastasis.
    Mol Cancer Ther. 2018 Sep 6. pii: 1535-7163.MCT-17-1198.
    PubMed     Abstract available

    July 2018
  30. SUDA K, Murakami I, Yu H, Kim J, et al
    CD44 facilitates epithelial to mesenchymal transition phenotypic change at acquisition of resistance to EGFR kinase inhibitors in lung cancer.
    Mol Cancer Ther. 2018 Jul 26. pii: 1535-7163.MCT-17-1279.
    PubMed     Abstract available

    June 2018
  31. SHIN DH, Jo JY, Han JY
    Dual targeting of ErbB2/ErbB3 for treatment of SLC3A2-NRG1-mediated lung cancer.
    Mol Cancer Ther. 2018 Jun 29. pii: 1535-7163.MCT-17-1178.
    PubMed     Abstract available

  32. NJATCHA C, Farooqui M, Kornberg A, Johnson DE, et al
    STAT3 Cyclic Decoy Demonstrates Robust Antitumor Effects in Non-Small Cell Lung Cancer.
    Mol Cancer Ther. 2018 Jun 11. pii: 1535-7163.MCT-17-1194.
    PubMed     Abstract available

    April 2018
  33. BOCKORNY B, Rusan M, Chen W, Liao RG, et al
    RAS-MAPK reactivation facilitates acquired resistance in FGFR1-amplified lung cancer and underlies a rationale for upfront FGFR-MEK blockade.
    Mol Cancer Ther. 2018 Apr 13. pii: 1535-7163.MCT-17-0464.
    PubMed     Abstract available

    February 2018
  34. HIRANO T, Yasuda H, Hamamoto J, Nukaga S, et al
    Pharmacological and structural characterizations of naquotinib, a novel third generation EGFR tyrosine kinase inhibitor, in EGFR mutated non-small-cell lung cancer.
    Mol Cancer Ther. 2018 Feb 21. pii: 1535-7163.MCT-17-1033.
    PubMed     Abstract available

    October 2017
  35. YAMADA T, Amann JM, Tanimoto A, Taniguchi H, et al
    Histone deacetylase inhibition enhances the antitumor activity of a MEK inhibitor in lung cancer cells harboring RAS mutations.
    Mol Cancer Ther. 2017 Oct 27. pii: molcanther.0146.2017.
    PubMed     Abstract available

    August 2017
  36. AKENO N, Reece AL, Callahan M, Miller AL, et al
    Trp53 Mutants Drive Neuroendocrine Lung Cancer through Loss-of-Function Mechanisms with Gain-of-Function Effects on Chemotherapy Response.
    Mol Cancer Ther. 2017 Aug 28. pii: molcanther.0353.2017.
    PubMed     Abstract available

  37. WATANABE S, Yoshida T, Kawakami H, Takegawa N, et al
    T790M-selective EGFR-TKI combined with dasatinib as an optimal strategy for overcoming EGFR-TKI resistance in T790M-positive non-small cell lung cancer.
    Mol Cancer Ther. 2017 Aug 24. pii: molcanther.0351.2017.
    PubMed     Abstract available

    July 2017
  38. SHIEN K, Papadimitrakopoulou VA, Ruder D, Behrens C, et al
    JAK1/STAT3 activation through a proinflammatory cytokine pathway leads to resistance to molecularly targeted therapy in non-small cell lung cancer.
    Mol Cancer Ther. 2017 Jul 20. pii: molcanther.0148.2016.
    PubMed     Abstract available

    May 2017
  39. GAUTAM J, Ku JM, Regmi SC, Jeong H, et al
    Dual inhibition of NOX2 and receptor tyrosine kinase by BJ-1301 enhances anticancer therapy efficacy via suppression of autocrine stimulatory factors in lung cancer.
    Mol Cancer Ther. 2017 May 23. pii: molcanther.0915.2016.
    PubMed     Abstract available

  40. RAIMBOURG J, Joalland MP, Cabart M, de Plater L, et al
    Sensitization of EGFR wild-type non-small cell lung cancer cells to EGFR-tyrosine kinase inhibitor erlotinib.
    Mol Cancer Ther. 2017 May 18. pii: molcanther.0075.2017.
    PubMed     Abstract available

  41. ROSS KC, Andrews AJ, Marion CD, Yen TJ, et al
    Identification of the serine biosynthesis pathway as a critical component of BRAF inhibitor resistance of melanoma, pancreatic, and non-small cell lung cancer cells.
    Mol Cancer Ther. 2017 May 12. pii: molcanther.0798.2016.
    PubMed     Abstract available

  42. LAM LT, Lin X, Faivre EJ, Yang Z, et al
    Vulnerability of small cell lung cancer to apoptosis induced by the combination of BET bromodomain proteins and BCL2 inhibitors.
    Mol Cancer Ther. 2017 May 3. pii: molcanther.0459.2016.
    PubMed     Abstract available

  43. CHATTERJEE S, Huang EH, Christie I, Kurland BF, et al
    Acquired Resistance to the Hsp90 Inhibitor, Ganetespib, in KRAS-Mutant NSCLC Is Mediated via Reactivation of the ERK-p90RSK-mTOR Signaling Network.
    Mol Cancer Ther. 2017;16:793-804.
    PubMed     Abstract available

    April 2017
  44. MANUEL-MANRESA P, Korrodi-Gregorio L, Hernando E, Villanueva A, et al
    Novel indole-based tambjamine-analogues induce apoptotic lung cancer cell death through p38 mitogen-activated protein kinase activation.
    Mol Cancer Ther. 2017 Apr 10. pii: molcanther.0752.2016.
    PubMed     Abstract available

  45. GIMENEZ-XAVIER P, Pros E, Bonastre E, Moran S, et al
    Genomic and molecular screenings identify different mechanisms for acquired resistance to MET inhibitors in lung cancer cells.
    Mol Cancer Ther. 2017 Apr 10. pii: molcanther.0104.2017.
    PubMed     Abstract available

  46. SALGIA R
    MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale.
    Mol Cancer Ther. 2017;16:555-565.
    PubMed     Abstract available

    March 2017
  47. WOO JK, Jang JE, Kang JH, Seong JK, et al
    Lectin, galactoside-binding soluble 3 binding protein promotes 17-N-Allylamino-17-demethoxygeldanamycin resistance through PI3K/Akt pathway in lung cancer cell line.
    Mol Cancer Ther. 2017 Mar 23. pii: molcanther.0574.2016.
    PubMed     Abstract available

    January 2017
  48. HAAK AJ, Appleton KM, Lisabeth EM, Misek SA, et al
    Pharmacological Inhibition of Myocardin-related Transcription Factor Pathway Blocks Lung Metastases of RhoC-Overexpressing Melanoma.
    Mol Cancer Ther. 2017;16:193-204.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.